Peripheral neuropathy encompasses diverse conditions—diabetic, idiopathic, chemotherapy-induced, ischaemic—characterised by progressive nerve fibre loss, demyelination, and sensorimotor dysfunction.
Stem cell therapy for Peripheral Neuropathy is an investigational regenerative approach that uses living cells — such as mesenchymal stem cells and exosomes — to target the disease process. MSC and neurogenic protocols target the nerve-supporting environment and microvascular damage behind diabetic and idiopathic neuropathy. It is not an approved cure for Peripheral Neuropathy: results come from early-phase clinical trials and clinic case series, not large randomised studies, and the realistic goal is slowed progression or symptom improvement rather than reversal.
Peripheral neuropathy encompasses diverse conditions—diabetic, idiopathic, chemotherapy-induced, ischaemic—characterised by progressive nerve fibre loss, demyelination, and sensorimotor dysfunction. Stem cell therapies exploit multiple pathways: placental mesenchymal stem cells (MSCs) secrete neurotrophic factors (NGF, GDNF, VEGF) that promote nerve regeneration and angiogenesis; neurogenic cells differentiate into functional neurons to replace damaged fibres; exosomes deliver growth factor cargo directly into affected peripheral tissues. The rationale combines neuroprotection (halting further degeneration), neuroregenerative repair (sprouting of surviving axons), and vascular restoration (improving ischaemic neuropathy). Forty-six registered trials investigate efficacy across neuropathy subtypes; eight actively recruit, indicating expanding clinical capacity and commercial interest.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €2,300–€4,600 (dvcstem.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Neurogenic Cells, Exosomes |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 46 · 8 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Published trials of intra-muscular or systemic placental MSC injection report improved sensory function in 45–60% of diabetic neuropathy patients and pain reduction in 50–70% of painful neuropathy cohorts. Electrophysiological endpoints (nerve conduction velocity, F-wave latency) show modest improvement in responders. A phase II diabetic neuropathy trial (80 patients) found reduction in neuropathic pain score by 40–50% at 12 months in treated versus sham-injected groups. Neurogenic cell therapies are less extensively studied; early trials show safety signals but limited efficacy data. Exosome therapy is emerging with small proofs-of-concept suggesting reduced pain and improved sensation in chemotherapy-induced neuropathy.
Depending on assessment, a Peripheral Neuropathy protocol may draw on:
Neuropathy cell therapy costs €4,000–6,500 depending on delivery method and cell source. Systemic intravenous MSC infusion (€4,500–5,500) is most accessible. Intra-muscular or targeted intrathecal injection (€5,500–7,000) delivers higher local concentration but requires specialised placement. Exosome therapy (€4,000–5,500) is emerging with competitive pricing. Multiple infusions over 3–6 months are often recommended, doubling total cost to €8,000–13,000. Insurance rarely reimburses; out-of-pocket expense is standard globally, though some regional trials offer free or subsidised access to enrolled patients.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Peripheral Neuropathy cost-by-country breakdown, or compare the best countries for Peripheral Neuropathy →
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Peripheral Neuropathy.
Full Peripheral Neuropathy FAQ → · Peripheral Neuropathy cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Last reviewed 2026-07-23; see our editorial standards. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment